Monoclonal antibody therapy was authorized for emergency use in the United States in November last year after it was used to treat former President Donald Trump.
Mexico City (apro).- In certain cases of covid-19, the World Health Organization (WHO), recommends that a combination be used between imdevimab (which uses monoclonal antibodies) and casirivimab (which use monoclonal antibodies).
Janet Díaz, head of clinical care at the United Nations agency, said: “This is a huge improvement in the care of covid-19 patients.”
It was approved for emergency use in the United States after it was administered to former President Donald Trump. Treatments that are not covered by insurance can cost thousands of dollars.
These drugs should only be used for patients at high risk with moderate or severe symptoms.
“Casirivimab or imdevimab can significantly lower the risk of hospitalization. However, all patients should be treated, even if they are at highest risk. Recommendation guide.
In addition, he added that the team studying drug use determined that the threshold for most people to be willing to receive treatment is “the risk of hospitalization due to covid-19 exceeds 10%”.
The guidelines note that there are no reliable tools that can predict the hospitalization risk for people infected by COVID-19.
To produce this therapy, the Swiss pharmaceutical company Roche has partnered up with Regeneron.
Unitaid, the United Nations health agency, is in negotiations with Roche to lower their prices and distribute them worldwide.
WHO spoke with Roche about the possibility of UNICEF giving the drug to them.
WHO recommends based upon data from a June study that looked at 9,000 patients in the United Kingdom. The study found that the treatment decreased mortality among patients who had an impaired immune system.
Dr. Diaz stated that they are collecting information from the UK and sharing it with others. He also said that “we see important benefits.”
This therapy has been available on the market for decades. It can also be used to treat other diseases such as cancer. It’s based on monoclonal antibody drugs, which mimic natural antibodies that the body produces to fight infections.